Mother-to-child transmission of HIV-1: association with malaria prevention, anaemia and placental malaria.
OBJECTIVE
Malaria infection may impact on mother-to-child transmission (MTCT) of HIV-1. Prevention of malaria in pregnancy could thus potentially affect MTCT of HIV. We studied the impact of intermittent preventive treatment during pregnancy (IPTp) on HIV-1 MTCT in southern Mozambique.


METHODS
A total of 207 HIV-positive Mozambican pregnant women were enrolled in the study as part of a randomized placebo-controlled trial of two-dose sulfadoxine-pyrimethamine (SP) IPTp in women receiving single-dose nevirapine to prevent MTCT of HIV. HIV RNA viral load, maternal anaemia and peripheral and placental malaria were assessed at delivery. Infant HIV status was determined by DNA polymerase chain reaction (PCR) at 1 month of age.


RESULTS
There were 19 transmissions of HIV in 153 mother-infant pairs. IPTp with SP did not have a significant impact on MTCT (11.8% in the SP group vs. 13.2% in the placebo group; P=0.784) or on maternal HIV RNA viral load [16 312 (interquartile range {IQR} 4076-69 296) HIV-1 RNA copies/mL in the SP group vs. 18 274 (IQR 5471-74 104) copies/mL in the placebo group; P=0.715]. In multivariate analysis, maternal HIV RNA viral load [adjusted odds ratio (AOR) 19.9; 95% confidence interval (CI) 2.3-172; P=0.006] and anaemia (haematocrit <33%; AOR 7.5; 95% CI 1.7-32.4; P=0.007) were independent risk factors for MTCT. Placental malaria was associated with a decrease in MTCT (AOR 0.23; 95% CI 0.06-0.89; P=0.034).


CONCLUSIONS
IPTp with SP was not associated with a significant impact on MTCT of HIV. Maternal anaemia was an independent risk factor for MTCT.
Naniche
D
D
Barcelona Center for International Health Research (CRESIB), Hospital Clinic, Universitat de Barcelona, Barcelona, Spain. dsuzanne@clinic.ub.es
Lahuerta
M
M
Bardaji
A
A
Sigauque
B
B
Romagosa
C
C
Berenguera
A
A
Mandomando
I
I
David
C
C
Sanz
S
S
Aponte
J
J
Ordi
J
J
Alonso
P
P
Menendez
C
C
D000328:Adult; D000740:Anemia / Q000469:parasitology / Q000821:virology; D019380:Anti-HIV Agents / Q000627:therapeutic use; D000962:Antimalarials / Q000627:therapeutic use*; D018791:CD4 Lymphocyte Count; D004338:Drug Combinations; D005260:Female; D015658:HIV Infections / Q000188:drug therapy / Q000635:transmission*; D015497:HIV-1; D006801:Humans; D007231:Infant, Newborn; D016778:Malaria, Falciparum / Q000188:drug therapy* / Q000635:transmission / Q000821:virology; D009073:Mozambique; D019829:Nevirapine / Q000627:therapeutic use; D010922:Placenta Diseases / Q000469:parasitology / Q000821:virology; D016133:Polymerase Chain Reaction; D011247:Pregnancy; D011250:Pregnancy Complications, Hematologic / Q000209:etiology; D011251:Pregnancy Complications, Infectious / Q000517:prevention & control*; D011739:Pyrimethamine / Q000627:therapeutic use*; D012367:RNA, Viral; D013413:Sulfadoxine / Q000627:therapeutic use*; D019562:Viral Load
D019380:Anti-HIV Agents; D000962:Antimalarials; D004338:Drug Combinations; D012367:RNA, Viral; C001205:fanasil, pyrimethamine drug combination; D013413:Sulfadoxine; D019829:Nevirapine; D011739:Pyrimethamine